In WM, the presence of wild-type MYD88 has been shown to confer a higher risk of HT [18, 27, 28] associated with carrying a higher risk of mutation in several genes that contribute to NF-kB signaling, similar to the genetic profile of de novo DLBCL [29, 30]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.